Zerbor Arcturus Therapeutics ( NASDAQ: ARCT ) said it will file an Investigational New Drug application for a phase 2 multiple ascending dose study of cystic fibrosis asset ARCT-032 in the next 60 days. The study is designed to determine a safe and effective dose in patients with the disease who do not improve with CFTR modulators. The company also said that it will expand its phase 2 program for ARCT-810, its candidate for ornithine transcarbamylase deficiency, a urea cycle disorder, by enrolling patients with more severe disease.
More on Arcturus Therapeutics Arcturus: A Hidden Gem In The Biotech Sector Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy Arcturus gains after early-stage data for cystic fibrosis therapy.